Eledon appoints Jan Hillson, M.D. as independent director; grants option for 40,000 shares

Eledon Pharmaceuticals, Inc.

Jan Hillson, M.D. appointed to Eledon board effective July 1, 2021; qualifies as independent under Nasdaq rules.
Received option to buy 40,000 shares at $7.68 per share; vests 20,000 on first anniversary, 20,000 on second anniversary.
Dr. Hillson will enter Eledon's standard indemnification agreement; no family relationships with officers/directors.
No arrangements or understandings with any other person regarding her appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jan Hillson, M.D.

Director

ELDN · Eledon Pharmaceuticals, Inc.

Effective: 2021-07-01
Filed: July 2, 2021, 7:59 PM ET

On July 1, 2021, Jan Hillson, M.D. was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jan Hillson, M.D. was appointed as Director at Eledon Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 1, 2021, Jan Hillson, M.D. was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”).

View on SEC.gov

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-035584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.